Treatment-Associated Second Primary Malignancy in Oncology Clinical Trials
Tommy Fu, Celgene Robert Knight, Celgene *Qiang (Casey) Xu, Celgene Zhinuan Yu, Celgene Jingshan Zhang, Celgene Keywords: cancer survival and outcome, second malignancy, second tumor The rapid development of oncology treatments in recent decades results in a significant increase in the number of cancer survivors. One of the most serious events experienced by this growing and heterogeneous population is the diagnosis of a second primary malignancy (SPM). Among various risk factors for SPM, e.g. cancer treatments, environmental exposures, genetic susceptibility, and simply longer survival etc., treatment-associated risks has brought increasingly more attention, especially in a regulatory setting. In this presentation, a time-to-event endpoint SPM-free survival, which denotes the time of being alive without SPM after using a treatment, is proposed to assess the benefit-risk profile of a particular treatment that may potentially cause SPMs. Simulations and clinical data are used to examine the performance of this endpoint in different scenarios. Challenges of the analysis, such as SPMs being rare events and requiring long-term follow-up, are discussed.
|
Key Dates
-
November 1 - December 17, 2013
Online proposal submission for a session, short course and Town Hall Open -
January 6 - March 11, 2014
Online proposal submission for Roundtables Open -
April 30 - May 28, 2014
Abstract Submission Open -
June 4, 2014
Online Registration Opens -
August 8 - August 22, 2014
Invited Abstract Editing -
August 11, 2014
Short Course materials due from Instructors -
September 1, 2014
Housing Deadline -
September 15, 2014
Cancellation Deadline and Registration Closes @ 11:59 pm EDT -
September 22 - September 24, 2014
Marriott Wardman Park, Washington, DC